<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808287</url>
  </required_header>
  <id_info>
    <org_study_id>2012-07</org_study_id>
    <nct_id>NCT01808287</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve/ The SAPIEN 3 Study</brief_title>
  <acronym>SAPIEN3</acronym>
  <official_title>Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and device success of the Edwards SAPIEN 3
      Transcatheter Heart Valve (S3 THV) and the Edwards Commander and Certitude Delivery Systems
      in patients with symptomatic, severe aortic stenosis who are indicated for aortic valve
      replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, prospective, multicenter safety and device success study. Two
      hundred fifty (250) patients are planned to be enrolled at up to 20 participating
      investigational centers in Europe and Canada. Patient participation will last for a minimum
      of 5 years. Patients will be assessed at the following intervals: baseline, hospital
      discharge, 30 days, 1 year and annually thereafter for a minimum of 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality rate</measure>
    <time_frame>30 days post-index procedure</time_frame>
    <description>NAP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety endpoints(VARC II)</measure>
    <time_frame>Discharge or 72 hours (whichever is longer), 30 days, 1 and 5 years post-index procedure.</time_frame>
    <description>safety endpoints
composite of mortality, and major complications including THV-related dysfunction major bleeds MI new conduction abnormality new onset of AF time-related valve safety composite of valve structural deterioration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>High risk population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAPIEN 3 transcatheter heart valve was implanted in high risk patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate risk population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAPIEN 3 transcatheter heart valve was implanted in intermediate risk patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards SAPIEN 3 Transcatheter Heart Valve</intervention_name>
    <description>The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).</description>
    <arm_group_label>High risk population</arm_group_label>
    <arm_group_label>Intermediate risk population</arm_group_label>
    <other_name>TAVR</other_name>
    <other_name>TAVI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe symptomatic calcific aortic valve stenosis with:

               1. High surgical risk: STS Score ≥ 8 or EuroSCORE ≥ 15 (first 50 patients),

               2. High to Intermediate surgical risk: STS Score ≥ 4 or EuroSCORE ≥ 10 (patients 51
                  to 150).

               3. Intermediate surgical risk: STS Score 4 to 8 or Logistic EuroSCORE 10 to 15
                  (subsequent patients); except for 20mm valve implants (STS Score &gt; 4 or EuroSCORE
                  ≥ 10).

          2. Age ≥ 75 years

          3. NYHA ≥ II

          4. Heart team (including examining cardiac surgeon) agrees on eligibility including
             assessment that TAVR is appropriate.

          5. Study patient has provided written informed consent to comply with all of the study
             procedures and follow-up visits.

        Exclusion Criteria:

          1. Non-calcified aortic valve

          2. Acute myocardial infarction ≤ 30 days before the intended treatment

          3. Untreated clinically significant coronary artery disease requiring revascularization.

          4. Aortic valve is a congenital unicuspid or congenital bicuspid valve.

          5. Mixed aortic valve disease (with predominant aortic regurgitation)

          6. Preexisting bioprosthetic valve or ring in any position

          7. For Intermediate Risk patients enrolled under inclusion criterion 1.c) patients with
             untreated pre-existing conduction disturbances (AV Block and Bundle Branch Block).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Webb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital Vancouver (Canada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Thomas Walther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerkhoff Heartcenter Bad Nauheim (Germany)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1 Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval, Institut universitaire de cardiologie et de pneumologie de Quebec</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massy, Institut Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris, Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Heartcenter</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitares Herzzentrum Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum Kalsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Koln</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London St. Thomas's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust Hospital</name>
      <address>
        <city>London</city>
        <zip>W1G 8PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Vahanian A, Urena M, Walther T, Treede H, Wendler O, Lefèvre T, Spence MS, Redwood S, Kahlert P, Rodes-Cabau J, Leipsic J, Webb J. Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial. EuroIntervention. 2016 Jun 12;12(2):e235-43. doi: 10.4244/EIJV12I2A37.</citation>
    <PMID>27290682</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Aortic Stenosis</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

